DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma.
复制标题
DTIC、CCNU、博来霉素和长春新碱 (BOLD) 治疗转移性黑色素瘤。
DOI：
10.1002/1097-0142(19801201)46:11
复制
发表时间：
1980
期刊：
影响因子：
6.2
通讯作者：
Huang,AT
中科院分区：
文献类型：
--
作者：
Seigler,HF;LucasJr,VS;Pickett,NJ;Huang,AT
从1977年1月到1978年4月，连续91名没有接受过任何化疗的转移性IV期黑色素瘤患者开始接受治疗。治疗方案包括博莱霉素(B)，第1疗程皮下注射7.5U，后续疗程第1、4d皮下注射15单位，长春新碱或长春新碱(O)1 mg/m2静滴，第1、5天静脉滴注长春新碱或长春新碱(L)80 mg/m2。第1天静脉滴注DTIC(D)200 mg/m2，第1~5天静脉滴注DTIC(D)200 mg/m2。可评价的患者(72例)是那些在内脏和皮肤上有可测量的肿瘤的患者。肿瘤完全消退(CR)7例(9%)，部分消退(PR)22例(31%)(肿瘤消退50%以上)，病情稳定12例(17%)，进展31例(43%)。缓解、缓解和病情稳定的患者(41例)的中位生存期为67周，而无反应者(31例)的中位生存期为20周(P<；0.0001)。博莱霉素-长春新碱-碘莫司汀-DTIC(BOLD)方案是治疗转移性黑色素瘤的有效替代方案，有反应的患者有良好的肿瘤反应和生存期延长。其总体毒性为轻度至中度。
Treatment of 91 consecutive patients having metastatic, Stage IV melanoma who had not received any previous chemotherapy was begun between January 1977 and April 1978. The therapy included bleomycin (B) at 7.5 units subcutaneously in the first course and 15 units in subsequent courses on days 1 and 4; vincristine or Oncovin (O) at 1 mg/m2intravenously on days 1 and 5; CCNU or lomustine (L) at 80 mg/m2p.o. on day 1 and DTIC (D) 200 mg/m2intravenously on days 1 through 5. Evaluable patients (72) were those who had measurable tumors in the viscera and on the skin. Seven patients (9%) responded with complete tumor regression (CR), 22 (31%) with partial regression (PR) (50% or more tumor regression), 12 (17%) with stabilization of disease, and 31 (43%) with progression of the disease. Patients who responded with CR, PR, and stable disease (41 patients) had a median survival of 67 weeks, while those who did not respond (31 patients) had a median survival of 20 weeks (P< .0001). Overall median survival was 31 weeks.The bleomycin‐Oncovin‐Iomustine‐DTIC (BOLD) regimen is an effective alternative treatment for metastatic melanoma; there is good tumor response and prolongation of survival in the responding patients. Its overall toxicity is mild to moderate.